Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
29 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


RSS FeedsKazia paxalisib Phase II interim data
(World News Science)

 
 

7 april 2020 04:32:12

 
Kazia paxalisib Phase II interim data
(World News Science)
 


ASX RELEASE 7 April 2020 KAZIA`S PAXALISIB SHOWS POSITIVE OVERALL SURVIVAL SIGNAL IN PHASE II GLIOBLASTOMA STUDY Overall survival (OS) of 17.7 months, vs. 12.7 months for existing standard of care Longest-treated patient remains progression-free 19 months after diagnosis Sydney, 7 April 2020 - Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer. Key Points Interim analysis of Part A (escalation cohort) (n=9) showed median overall survival (OS) of 17.7...


 
23 viewsCategory: Science
 
Your weekly video guide to calm and connection in the COVID-19 storm
(World News Science)
Coronavirus live news: Boris Johnson in intensive care as Trump sends prayers
(World News Science)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten